Treatment for Cancer of Pancreas

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Cancer of Pancreas+1 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial tests a new cancer vaccine given with or without a low dose of chemotherapy. The goal is to see if it is safe and effective.

Eligible Conditions
  • Cancer of Pancreas
  • Malignant Neoplasm of Pancreas

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: total of 13 years with 6 months between vaccines.

Year 13
Disease free overall survival.

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

0 Treatment Group

72 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 2

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: total of 13 years with 6 months between vaccines.

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
534 Previous Clinical Trials
31,030 Total Patients Enrolled
The Skip Viragh FoundationOTHER
3 Previous Clinical Trials
98 Total Patients Enrolled
Lei Zheng, MDPrincipal InvestigatorJohns Hopkins University
3 Previous Clinical Trials
71 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a history of surgically resected and pathologically proved AJCC stage I or stage II adenocarcinoma of the head, neck, or uncinate of the pancreas.
You have provided informed consent.
You have adequate renal function.
You have hematologic function.
You have a performance status of 0 or 1.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: November 3rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.